SCHEMBL5217502

SCHEMBL5217502

CCOC(=O)C(C)c1ccc(N2CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.57
MEN1 O00255 1/20 0.57
HPGD P15428 1/20 0.57
KMT2A Q03164 1/20 0.57
DRD4 P21917 3/20 0.54
HTR7 P34969 2/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
HTR2B P41595 1/20 0.52
ALDH1A1 P00352 1/20 0.51
PRMT1 Q99873 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
POLB P06746 1/20 0.48
SIGMAR1 Q99720 1/20 0.48
LMNA P02545 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27619094 0.86 DRD4 (0.61) MAPTMEN1KMT2ADRD4HTR7
SCHEMBL3318522 0.81 PRMT1 (0.68) MAPTMEN1HPGDKMT2ADRD4
SCHEMBL10714300 0.80 DRD4 (0.55) MAPTMEN1HPGDKMT2ADRD4
SCHEMBL15247183 0.79 DRD4 (0.71) MAPTDRD4HTR2AHTR2CHTR2B
SCHEMBL11990246 0.78 DRD4 (0.64) MAPTMEN1KMT2ADRD4HTR2A
SCHEMBL3313145 0.77 ALDH1A1 (0.57) MAPTMEN1HPGDKMT2AALDH1A1
SCHEMBL10714295 0.77 DRD4 (0.51) MAPTMEN1HPGDKMT2ADRD4
SCHEMBL20795864 0.76 MEN1 (0.51) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL27619095 0.76 DRD4 (0.60) MAPTMEN1KMT2ADRD4HTR7
SCHEMBL3310151 0.76 ATM (0.56) MAPTMEN1KMT2AALDH1A1PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1276732-B1 AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ DOMPE PHA R MA SPA RES & MFG (IT) 2007-09-26 EP disclosed
US-7217707-B2 Amide of R-2-(aminoaryl)-propionic acid for use in the prevention of leucocyte activation DOMPE S.P.A. (IT) 2007-05-15 US disclosed
US-20040186146-A1 Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation DOMPÉ FARMACEUTICI S.P.A. (IT) 2004-09-23 US disclosed
EP-1276732-A1 AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ Dompé S.P.A. (IT) 2003-01-22 EP disclosed
WO-2001079189-A2 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' Dompé S.p.A. (IT) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186146-A1 Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation MMP8, CXCL8, HCAR2 MAPT 4278/4885MEN1 4756/4885HPGD 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.